Hebesh, E., Basiouny, A., Shaheen, A., Soliman, S., Alhassanin, S., Ateya, H. (2025). Assessment of Fatigue in Patients with Chronic Myeloid Leukemia Receiving Targeted Therapy: A Cross-Sectional Study. Research in Oncology, 21(1), 11-18. doi: 10.21608/resoncol.2025.340487.1215
Eman H. Hebesh; Abeer M. Basiouny; Amgad A. Shaheen; Shaimaa S. Soliman; Suzan Alhassanin; Heba A. Ateya. "Assessment of Fatigue in Patients with Chronic Myeloid Leukemia Receiving Targeted Therapy: A Cross-Sectional Study". Research in Oncology, 21, 1, 2025, 11-18. doi: 10.21608/resoncol.2025.340487.1215
Hebesh, E., Basiouny, A., Shaheen, A., Soliman, S., Alhassanin, S., Ateya, H. (2025). 'Assessment of Fatigue in Patients with Chronic Myeloid Leukemia Receiving Targeted Therapy: A Cross-Sectional Study', Research in Oncology, 21(1), pp. 11-18. doi: 10.21608/resoncol.2025.340487.1215
Hebesh, E., Basiouny, A., Shaheen, A., Soliman, S., Alhassanin, S., Ateya, H. Assessment of Fatigue in Patients with Chronic Myeloid Leukemia Receiving Targeted Therapy: A Cross-Sectional Study. Research in Oncology, 2025; 21(1): 11-18. doi: 10.21608/resoncol.2025.340487.1215
Assessment of Fatigue in Patients with Chronic Myeloid Leukemia Receiving Targeted Therapy: A Cross-Sectional Study
1Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2Clinical Pathology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
3Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt
4Public Health and Community Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Abstract
Background: Fatigue is a common side effect of tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML), leading to reduced health-related quality of life (HRQoL) and decreased treatment adherence. Aim: To evaluate the severity of fatigue and the factors influencing it, including vitamin D deficiency, in CML patients undergoing TKI therapy. Methods: This cross-sectional observational study included 60 CML patients on TKI therapy. Fatigue severity was assessed using the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale, with severe fatigue defined as a score of ≤30. HRQoL was evaluated using the Functional Assessment of Cancer Therapy-General (FACT-G). Vitamin D levels were measured, and sociodemographic, clinical, and laboratory data were collected from patient records. Results: The mean age of participants was 44.6 years, with 34 (57%) being female. The median duration of treatment was 82.3 months. Severe fatigue was reported by 29 (48%) participants. Univariate analysis showed significant associations between severe fatigue and factors such as TKI dose, adherence to treatment, time to first complete cytogenetic response, and vitamin D deficiency (p = 0.009, 0.006, 0.021 and <0.001; respectively). Multivariate analysis confirmed a significant association between severe fatigue and vitamin D deficiency. Additionally, severe fatigue and vitamin D deficiency were both significantly linked to poorer overall HRQoL. Conclusion: Healthcare providers should address factors influencing fatigue, particularly vitamin D deficiency, in the management of CML patients receiving TKI therapy.
View on SCiNiTO
Top